Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant vs Tamoxifen in HR+ Early Breast Cancer After AI Toxicity
NCT05128773Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of amcenestrant in breast cancer, sponsored by Sanofi. Started Feb 2022; status: terminated.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05128773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128773.